Evolent Health (FRA:9EH) Piotroski F-Score: 5 (As of Jul. 21, 2026) — 25% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9EH Evolent Health Inc FRA:9EH
63 GF Score
Price €5.05
GF Value €9.69
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Evolent Health Piotroski F-Score?

Evolent Health FRA:9EH +3.06% 63 Piotroski F-Score is 5 as of Jul. 21, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates FRA:9EH with a GF Score™ of 63/100 and a GF Value™ of €9.69 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 646 Healthcare Providers & Services companies, Evolent Health ranks better than 54.49% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Evolent Health has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Evolent Health's Piotroski F-Score or its related term are showing as below:

FRA:9EH' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Evolent Health was 7. The lowest was 1. And the median was 4.

Evolent Health  (FRA:9EH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Evolent Health Piotroski F-Score Related Terms


Evolent Health Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Evolent Health's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolent Health Piotroski F-Score Chart

Evolent Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 3.00 5.00 4.00 5.00

Evolent Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 1.00 4.00 5.00 5.00

FRA:9EH vs PHR, CTEV, MDRX: Piotroski F-Score Comparison

For the Health Information Services subindustry, Evolent Health's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Evolent Health's Piotroski F-Score falls into.


FRA:9EH
63GF Score
Evolent Health Inc FRA:9EH
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -17.251 + -17.776 + -366.478 + -23.037 = €-425 Mil.
Cash Flow from Operations was -26.3 + 13.472 + 41.675 + -0.851 = €28 Mil.
Revenue was 385.232 + 408.562 + 400.286 + 429.253 = €1,623 Mil.
Gross Profit was 87.034 + 85.007 + 83.054 + 72.465 = €328 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2454.442 + 2134.148 + 2090.347 + 1621.948 + 1625.203) / 5 = €1985.2176 Mil.
Total Assets at the begining of this year (Mar25) was €2,454 Mil.
Long-Term Debt & Capital Lease Obligation was €845 Mil.
Total Current Assets was €434 Mil.
Total Current Liabilities was €330 Mil.
Net Income was 1.483 + -20.846 + -21.776 + -59.772 = €-101 Mil.

Revenue was 601.198 + 559.882 + 617.448 + 447.375 = €2,226 Mil.
Gross Profit was 99.257 + 72.704 + 72.304 + 94.786 = €339 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2432.179 + 2299.376 + 2254.089 + 2429.913 + 2454.442) / 5 = €2373.9998 Mil.
Total Assets at the begining of last year (Mar24) was €2,432 Mil.
Long-Term Debt & Capital Lease Obligation was €613 Mil.
Total Current Assets was €673 Mil.
Total Current Liabilities was €684 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Evolent Health's current Net Income (TTM) was -425. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Evolent Health's current Cash Flow from Operations (TTM) was 28. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-424.542/2454.442
=-0.17296885

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-100.911/2432.179
=-0.04148996

Evolent Health's return on assets of this year was -0.17296885. Evolent Health's return on assets of last year was -0.04148996. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Evolent Health's current Net Income (TTM) was -425. Evolent Health's current Cash Flow from Operations (TTM) was 28. ==> 28 > -425 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=844.799/1985.2176
=0.42554479

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=613.383/2373.9998
=0.25837534

Evolent Health's gearing of this year was 0.42554479. Evolent Health's gearing of last year was 0.25837534. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=434.239/329.768
=1.31680151

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=673.339/683.665
=0.98489611

Evolent Health's current ratio of this year was 1.31680151. Evolent Health's current ratio of last year was 0.98489611. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Evolent Health's number of shares in issue this year was 111.905. Evolent Health's number of shares in issue last year was 115.315. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=327.56/1623.333
=0.20178238

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=339.051/2225.903
=0.15232065

Evolent Health's gross margin of this year was 0.20178238. Evolent Health's gross margin of last year was 0.15232065. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1623.333/2454.442
=0.66138577

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=2225.903/2432.179
=0.91518881

Evolent Health's asset turnover of this year was 0.66138577. Evolent Health's asset turnover of last year was 0.91518881. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Evolent Health has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Evolent Health (FRA:9EH) has a Piotroski F-Score of 5 as of Jul. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Evolent Health and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Evolent Health's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Evolent Health ranks #294 out of 646 companies in the Healthcare Providers & Services industry, placing it in the top 45.5%.
Is Evolent Health's Piotroski F-Score too high?
Evolent Health's current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Evolent Health's value of 5 is 0% at this industry median. Based on the distribution chart, Evolent Health ranks #294 out of 646 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Evolent Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's Piotroski F-Score compare to PHR and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #294 out of 646 companies for Piotroski F-Score. This puts Evolent Health in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Evolent Health's value of 5 is 0% at this benchmark. Historically, Evolent Health's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Evolent Health has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evolent Health's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Evolent Health and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (FRA:9EH) is currently considered Possible Value Trap. The stock's GF Value™ is €9.69, compared to a current price of €5.05 — trading 47.9% below its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 0% at the Healthcare Providers & Services industry median of 5.00. Evolent Health's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Evolent Health (FRA:9EH), the current Piotroski F-Score is 5 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolent Health (FRA:9EH) Overvalued in 2026?

Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued. The current stock price of €5.05 is trading 47.9% below its estimated GF Value™ of €9.69. GuruFocus considers Evolent Health to be Possible Value Trap.

Key valuation signals for FRA:9EH:

  • Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
  • GF Value™: €9.69 vs. price of €5.05 (47.9% below fair value)
  • GF Score™: 63/100 with 7 warning signs
  • Industry Position: 0% at the Healthcare Providers & Services median (#294 of 646)

No single metric tells the full story. See the FRA:9EH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evolent Health Business Description

Other Exchanges EVH:USA9EH:Germany
Address 1812 North Moore Street, Suite 1705, Arlington, VA, USA, 22209
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
63GF Score

Get the complete analysis for FRA:9EH

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.05
Price
€9.69
GF Value